

## **Calibrant Biosystems Announces Appointment of Dr. Satya Saxena as Vice-President of Research**

Calibrant Biosystems today announced the appointment of Dr. Satya Saxena as its Vice-President of Research. Dr. Saxena will lead Calibrant's proteomic technology and product development programs. His primary focus will include expanding and validating the Gemini™ platform technology beyond the initial programs in oncology. He will also oversee the continuing drug development efforts involving lead compounds in ovarian, brain, and breast cancer.

Dr. Saxena joins Calibrant from the National Institute on Aging, National Institutes of Health (NIH), where he served as Chief of the Proteomics and Mass Spectrometry Facility. While there, he steered the development of innovative proteomics technologies essential to the success of contemporary biomedical research. He collaborated with laboratory chiefs at the National Institute on Aging to apply creative approaches in the analysis of proteins and their modifications, characterizing complex protein mixtures critical to numerous disease pathways. Prior to the NIH, he played a key role in the development of statewide proteomics infrastructure in the State of New Mexico and University of Manitoba, Canada. Dr. Saxena received his PhD in Analytical Chemistry/Toxicology from All India Institute of Medical Sciences, and conducted his post-doctoral work at the Biomedical Research Centre in Vancouver, Canada and the Manitoba Institute of Cell Biology in Winnipeg, Canada.

Michael Salgaller, Ph.D., Chief Operating Officer, stated: "The Board and I are very pleased to have someone of Dr. Saxena's expertise and technical vision as our Vice-President of Research at Calibrant. As a leader in the field of proteomics, Satya brings critical technical development and scientific management capabilities. We believe his contributions will be broadly applicable to every aspect of our pipeline as we take Calibrant to the next stage of development as a leader in the field."

### About Calibrant Biosystems

Calibrant Biosystems is a Gaithersburg, MD biotechnology company specializing in targeted drug discovery from clinical tissue specimens. Calibrant's advanced Gemini(TM) discovery platform, which is compatible with both fresh and formalin-fixed archival tissues, provides the unique ability to comparatively map protein networks between different cell types within a single tissue section. With an initial focus on monoclonal antibody drug development in oncology, Calibrant is leveraging the Gemini(TM) platform for the development of first-in-class therapeutics for cancer and other major medical needs.

Contact

Dr. Michael Salgaller  
Chief Operating Officer  
Calibrant Biosystems  
910 Clopper Road, Suite 220N  
Gaithersburg, MD 20878  
Voice: 301-977-7900